CMS-2L2-23-001: Health Equity Data Access Program (HEDAP)
Closed
This grant is closed. A newer notice from the same program is forecast: Health Equity Data Access Program (HEDAP) (CMS-2L2-25-001). Status: Forecast, no dates yet. It is in our archive of Center for Medicare and Medicaid Services notices from 2023.
Center for Medicare and Medicaid Services offered grants of up to $90,000 to colleges and universities. It expected to make about 3 awards worth $270,000 in total. Applications closed on August 15, 2023.
From the official notice on Grants.gov, last changed June 29, 2023. Checked November 7, 2026.
- Award ceiling$90,000
- Total funding$270,000
- Expected awards3
- Cost sharingNot required
- Funding typeGrant
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| CMS-2L2-25-001 | July 25, 2024 | Forecast, no dates yet | Forecast |
Key dates
| Posted | June 29, 2023 |
|---|---|
| Deadline | August 15, 2023 |
| Archived by Grants.gov | September 14, 2023 |
Who can apply
This opportunity was open to colleges and universities.
- Public and State controlled institutions of higher education
- Private institutions of higher education
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
The Health Equity Data Access program (HEDAP provides funding for three (3) “seats” in the CMS Virtual Research Data Center (VRDC). HEDAP assists researchers in gaining access to CMS restricted data for minority health research. Seats, in this context are defined as an individual user with VRDC access. These researchers will conduct health services research focusing on, but not limited to, racial and ethnic minority groups; people with disabilities; members of the lesbian, gay, bisexual, transgender, and queer (LGBTQ+) community; individuals with limited English proficiency; individuals residing in rural areas; and individuals adversely affected by persistent poverty or inequality. The HEDAP supports specific applied research projects that relate to creative and innovative methods by using CMS data to identify, document, assess, and evaluate health disparities among Medicare and Medicaid and CHIP enrollees. The project should enhance the capacity of the researcher to understand and utilize CMS data in future research projects. Additionally, HEDAP encourages cutting-edge proposals that explore intersectionality. “Intersectionality” means that people belong to more than one group and, therefore, may have overlapping health and social inequities, as well as overlapping strengths and assets. Results of the HEDAP will provide CMS and its partners, (e.g. Quality Improvement Organizations, Hospital Engagement Networks, and other stakeholders) with actionable information on the subgroups of enrollees. This will aid the efforts of CMS and its agents to identify and eradicate health disparities in underserved populations. VRDC seat access will be funded for a period of 36 months each, based on the availability of funds.
Applying now
This notice no longer takes applications. Apply under the newer notice, CMS-2L2-25-001, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CMS-2L2-23-001 still open?
No. It closed on August 15, 2023. A newer notice is forecast: CMS-2L2-25-001, forecast, no dates yet.
Who can apply for Health Equity Data Access Program (HEDAP)?
Center for Medicare and Medicaid Services accepted applications from colleges and universities.
What is the deadline for Health Equity Data Access Program (HEDAP)?
Closed August 15, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $90,000 each. About $270,000 in total across about 3 awards.
Similar open grants
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
- Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)